Kestra Investment Management LLC Buys New Position in DexCom, Inc. $DXCM

Kestra Investment Management LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the third quarter, HoldingsChannel.com reports. The fund acquired 18,467 shares of the medical device company’s stock, valued at approximately $1,594,000.

Several other large investors also recently modified their holdings of DXCM. Retirement Systems of Alabama increased its holdings in shares of DexCom by 565.0% during the third quarter. Retirement Systems of Alabama now owns 539,049 shares of the medical device company’s stock valued at $46,515,000 after acquiring an additional 457,986 shares in the last quarter. Fulcrum Asset Management LLP lifted its holdings in shares of DexCom by 3,769.0% in the 3rd quarter. Fulcrum Asset Management LLP now owns 5,494 shares of the medical device company’s stock worth $476,000 after purchasing an additional 5,352 shares in the last quarter. Hohimer Wealth Management LLC grew its position in DexCom by 4.7% in the 3rd quarter. Hohimer Wealth Management LLC now owns 10,732 shares of the medical device company’s stock valued at $926,000 after purchasing an additional 478 shares during the period. Ethic Inc. increased its stake in DexCom by 0.7% during the 3rd quarter. Ethic Inc. now owns 23,744 shares of the medical device company’s stock valued at $2,049,000 after purchasing an additional 172 shares in the last quarter. Finally, Alta Advisers Ltd bought a new stake in DexCom during the 3rd quarter valued at $243,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of DXCM opened at $79.92 on Wednesday. The firm has a market cap of $29.81 billion, a PE ratio of 31.34, a PEG ratio of 1.34 and a beta of 1.45. The stock’s fifty day moving average price is $84.79 and its two-hundred day moving average price is $75.08. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.74 and a quick ratio of 1.40. DexCom, Inc. has a 1 year low of $55.84 and a 1 year high of $92.59.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.05. The company had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. DexCom’s revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.61 EPS. On average, equities research analysts forecast that DexCom, Inc. will post 2.68 EPS for the current year.

Insider Activity

In other DexCom news, Director Nicholas Augustinos sold 6,539 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $549,537.56. Following the transaction, the director directly owned 29,293 shares in the company, valued at $2,461,783.72. This represents a 18.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $88.37, for a total transaction of $226,669.05. Following the completion of the sale, the executive vice president directly owned 126,043 shares in the company, valued at $11,138,419.91. This represents a 1.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 22,822 shares of company stock worth $1,920,193. Company insiders own 0.28% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on DXCM shares. Wall Street Zen upgraded shares of DexCom from a “hold” rating to a “buy” rating in a report on Sunday, September 6th. Truist Financial set a $102.00 price target on DexCom and gave the company a “buy” rating in a research note on Friday, September 18th. JPMorgan Chase & Co. boosted their price objective on DexCom from $82.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 30th. Deutsche Bank Aktiengesellschaft increased their price objective on DexCom from $86.00 to $92.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Jefferies Financial Group increased their price objective on DexCom from $112.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $95.50.

DexCom Company Profile

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.